Search This Blog

Monday, May 27, 2024

United Airlines Plane Catches Fire At Chicago’s O'Hare Airport

 By Tom Ozimek of The Epoch Times

An engine caught fire on a United Airlines flight at Chicago’s O'Hare International Airport on May 27, causing the pilots to abort takeoff.

United Airlines flight 2091 from Chicago to Seattle experienced an engine fire at around 2 p.m. local time at O'Hare airport shortly before takeoff, a spokesperson for the Federal Aviation Administration (FAA) told The Epoch Times in an emailed statement.

The incident led the FAA to temporarily suspend arrivals to the airport, with normal operations resuming at around 2:45 p.m. local time, the spokesperson added.

The aircraft, an Airbus A320, was towed to the gate where passengers “safely deplaned,” per the FAA spokesperson.

A spokesperson for United Airlines confirmed in an emailed statement to The Epoch Times that the flight in question, which was scheduled to depart for Seattle-Tacoma International Airport, was delayed after experiencing an “issue” with the engine, “which our local ground crew and emergency responders immediately addressed.”

“The plane was towed to the gate, passengers deplaned normally and no injuries were reported. We are working to make alternative travel arrangements for customers,” the spokesperson added.

The United Airlines spokesperson said that 148 passengers and five crew members were on board the aircraft when the incident occurred.

“The fire department and medical personnel met the aircraft out of an abundance of caution,” the spokesperson said.

A post circulating on social media purportedly shows images and video of the grounded United Airlines flight 2091 with several fire trucks on standby.

While details of the engine fire remain unclear, it comes as a federal watchdog recently launched an audit of the FAA to evaluate its oversight of United Airlines’ maintenance programs after a run of safety events at the carrier were linked to mechanical problems.

https://www.zerohedge.com/markets/united-airlines-plane-catches-fire-chicagos-ohare-airport

Alzheimer's report highlights immense caregiver burden—and potential ways forward

 Some 7 million Americans live with Alzheimer's, and about 11 million provide unpaid care for them.

Dementia caregiving can present unique challenges, including financial burdens and , as well as .

A report this year from the Alzheimer's Association demonstrates the true cost of caregiving for those with the disease and calls to establish dementia care navigation throughout the U.S. to lift this burden.

Not only is the estimated value of unpaid care near $14 billion in Pennsylvania alone, the report also revealed emotional and physical tolls. Nearly 77% of Alzheimer's caregivers in the commonwealth reported a  and a third reported depression.

Alzheimer's was the fifth-leading cause of death in the U.S. in 2021. Prior to death, years are spent with health challenges and progressive deterioration from the disease.

"Most caregivers do fairly well in their role and report high levels of reward, but there is a small selection that experience adverse effects," said Jennifer Wolff, a professor in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health, specializing in older adult and caregiver quality of life. Those with issues tend to be providing high levels of care, she said. Wolff was not involved in the research.

"These results raise a number of challenges," said Wolff. "We currently do not have system-level solutions."

The report pulled data from dozens of databases and thousands of journal articles about dementia, caregiving, health, and economic costs. It examined metrics related to caregiver well-being and Alzheimer's disease projections over time, as well as solutions moving forward to address the crisis, namely bolstering dementia care navigation and easing access to resources. It encouraged private insurers and health systems to directly address dementia and dementia caregiving and called for better financial incentives for caregiving to expand the workforce.

More than half of caregivers reported "high" or "very high" emotional stress due to their roles.

"Dementia caregiving as a whole is very stressful and taxing," said Wolff. It can involve bearing witness to an array of behavioral changes and inconsistencies, including wandering, agitation, combativeness and, of course, memory lapses.

These caregivers help with more daily activities compared to other kinds of caregivers—including dealing with incontinence, bathing and feeding. More than other caregivers, they leave work early, take off work or quit their jobs entirely. And dementia caregivers are more likely to have had a stroke, heart disease, diabetes and cancer compared to other caregivers.

Some physical ailments could be due to growing older themselves: A third of dementia caregivers are 65 or older, per the report.

"There is evidence that they're in that age group where chronic conditions may (emerge)," said Karen Roberto, executive director of the Institute for Society, Culture and Environment and a senior fellow at the Virginia Tech Center for Gerontology, and who was not involved in the research. "They're dealing with their own issues."

But these caregivers also report high physical stress from their roles.

"The repetition and forgetting can grate on a caregiver," Roberto said. "This can trigger the stress of caregiving."

Clay Jacobs, executive director of the Alzheimer's Association of Greater Pittsburgh, said the results about chronic health issues with dementia caregivers were particularly concerning.

"We don't see that same level of challenge with other diseases," he said. "Most people take care of their loved ones at home as long as they can. Certainly, it has a tremendous impact."

These burdens are not equally distributed, either. Although Black and Hispanic Americans are more likely than whites to develop Alzheimer's, they're less likely to be diagnosed.

Two-thirds of unpaid caregivers were white, per the report; 10% were Black.

While Black American caregivers are more likely to experience a lack of resources from systemic health inequities, there's evidence that some report less of a sense of burden compared to other races. This could be because, in certain cultures, caregiving is seen as a family responsibility as opposed to something they should receive money or additional resources for, said Roberto.

"If you have means, you have a leg up," she said. "You have opportunities. That doesn't always mean you're going to get the services you need, because there's a limited amount of services available."

And even if they had access to services, Wolff said caregivers don't always want them or can't take time away to attend . Roberto said her research suggests some caregivers actually report higher levels of stress when utilizing services, and the Alzheimer's Association report supports this. Unpaid caregivers cite additional work, burden and confusion involved in seeking out resources, coordinating and managing care, leading to nearly one in five stating the experience is "very stressful."

The Alzheimer's Association report also estimates that 1 million additional care professionals will be needed by 2031 to manage the growing number of adults with dementia and Alzheimer's—the most workers needed than in any other occupation in the U.S.

And federal social security monies to support the older population could deplete as soon as 2035 unless Congress acts, according to an annual report from the U.S. Social Security Office, meaning patients and caregivers may not have the funds to hire in-home care.

The Centers for Medicare and Medicaid Services created the Guiding an Improved Dementia Experience (GUIDE) model last year to fund dementia care and support patients and caregivers longer term. The pilot program is expected to launch in July and run for eight years. It includes a 24/7 helpline and increased support for care coordination, in an effort to improve patient and caregiver quality of life and the dementia care navigation system overall.

Experts say it's a first step toward structural changes for dementia caregivers. The model is, for the first time, testing out built-in support for unpaid caregivers, and time will tell how it rolls out, said Wolff.

"I'm excited for the new era we're entering in," Jacobs said. "My hope is that when a caregiver does decide to reach out, there's no shortage of ways for them to do so."

Wolff is also researching how using the digital sphere can help support the dementia  network. This might involve easier navigation of the patient portal or telehealth appointments for caregivers who can't leave their patients unsupervised. Or it could mean establishing support within the primary care model and dementia clinics, so resources can be deployed in-house during regular doctor's visits.

Taking advantage of the digital sphere could be huge, said Carol Schramke, the director of behavioral neurology at Allegheny General Hospital and chair of the Ethics Committee for AGH and Allegheny Health Network. But it's important to note that many older adults aren't tech savvy, and symptoms can be improved with behavioral changes, she said.

Healthy eating, regular exercise, social experiences and adequate sleep can all lower the risk of developing . Taking a preventive approach may proactively chip away at the millions expected to develop the disease in the coming decades.

And if you're going to help someone else, you should make sure you're taking care of yourself, said Schramke.

"It's important to remember that helping other people is good for us," she said. "Especially if you're not completely at your wit's end, being able to provide care for someone who needs your help can be very rewarding. It's just about trying not to put the burden on one person."

2024 the Pittsburgh Post-Gazette, Distributed by Tribune Content Agency, LLC.

https://medicalxpress.com/news/2024-05-alzheimer-highlights-immense-caregiver-burden.html

Tlaib Speaks At Conference Connected With Terrorist Group

 Rashida Tlaib, a Congresswoman from Detroit and a member of the Democratic Socialists of America, spoke over the weekend at the "People's Conference for Palestine," linked to the Popular Front for the Liberation of Palestine (PFLP).

This group, an Arab nationalist movement with Marxist-Leninist ideology, is designated as a Foreign Terrorist Organization by the US. It has public-facing arms, such as Samidoun, working on behalf of the group, and active cells in many countries in Europe and North America. 

During the Saturday speech, Tlaib referred to members of the audience as the "squad" and demanded President Biden establish a "red line" on Israel's counteroffensive in Gaza. She criticized the president for "attacking the authority" of the International Criminal Court, which issued an arrest warrant for Israeli Prime Minister Benjamin Netanyahu last week over war crimes and crimes against humanity in Israel's mission to eliminate Hamas in Gaza. 

Among the speakers was Wisam Rafeedie, an activist linked to PFLP. The US State Department has designated the PFLP as a terrorist organization. 

According to the Director of National Intelligence, PFLP is a terrorist group based in the Gaza Strip and the West Bank. It unites Arab nationalism with Marxist-Leninist ideology. It promotes the destruction of "Israel as integral to the struggle to remove Western capitalism from the Middle East and ultimately establish a Communist Palestinian state with Jerusalem as its capital," the DNI writes on its website. 

DNI provides more valuable insight into the terror organization: 

The PFLP fostered links and carried out attacks with leftist militant groups across the world during the 1970s and was actively involved in the Second Intifada from 2000 to 2005, during which the group carried out suicide operations and launched multiple joint operations with other Palestinian terrorist groups. The PFLP's operational tempo has since declined, with only two attacks in the last five years, most recently in 2019 that killed an Israeli teen and injured multiple others.

"I don't need to tell you that you're on the right side," Tlaib said in her speech in Detroit, adding, "I don't need to. But I'll be damned if I wait ten years before they apologize to all of you for doing what was right at this moment."

A recent statement by Israel's Ministry of Defense specifies, "Samidoun organization was designated as a terrorist organization as it is part of the PFLP." 

"Representatives of the organization are active in many countries in Europe and North America, led by Khaled Barakat, who is part of the leadership of PFLP abroad. Barkat is involved with establishing militant cells and motivating terrorist activity in Judea & Samaria and abroad," MoD said. 

Barakat is married to leftist radical Charlotte Kates, the coordinator of Samidoun and a Rutgers University School of Law graduate. 

According to NGO MonitorPFLP and Samidoun "had a strong presence at encampments, demonstrations, and riots on American college campuses. Students have been documented carrying PFLP posters, flying the PFLP flag, hosting PFLP-linked speakers, and reading PFLP publications." 

The degrees of separation between PFLP and Samidoun are only a few steps, and now it should become increasingly apparent a terrorist group has been directly/indirectly fueling the chaos across America's elite colleges and universities. Yet, the Biden administration could care less, and the FBI is nowhere to be found publicly.  

As for Tlaib speaking at the PFLP-linked event in Detroit, we'll refrain from adding our commentary. Instead, here are some reactions from X users:

Where is the FBI?

https://www.zerohedge.com/political/absurd-radical-leftist-rashida-tlaib-speaks-conference-connected-terrorist-group

James Biden associate Keaton Langston pleads guilty to $51M Medicare fraud

 A former business associate of James Biden has agreed to plead guilty to conspiring to defraud Medicare of $51 million through a lab-testing company linked to the first brother.

Keaton Langston, 39, admitted to using pharmacies, durable medical equipment companies and a laboratory in which he had a financial interest to bill for unnecessary tests and orders, the Justice Department disclosed last week in court filings.

James Biden, 75, has not been accused of criminal wrongdoing and has sought to distance himself from Langston, whose father Joey Langston also was associated with the first brother.

Keaton Langston, a former business associate of James Biden, pleaded guilty to conspiring to defraud Medicare of $51 million.Photo by Chip Somodevilla/Getty Images

Keaton Langston founded Fountain Health, a lab company, in May 2017 and offered its services to rural hospital operator Americore Health, which later went bankrupt.

Records show James Biden was involved with Fountain Health in 2017 before connecting with Americore, which provided him in $600,000 in loans in 2018 as he allegedly vowed to use his political connections to secure foreign investors.

James passed $200,000 of the funds to Joe Biden in an alleged loan repayment.

Shortly after the lab firm launched, Joey Langston emailed James Biden and his son Keaton and three others on July 12, 2017, about an upcoming “meeting for Fountain Health partners,” Politico reported in February.

“Jim will report to the group the results of his discussions earlier today with a contact at [Blue Cross Blue Shield],” the elder Langston wrote. “There will also be discussion about how to proceed with the Union contacts that have been made by Jim and Keaton, within the last two weeks.”

Paul Fishman, an attorney for James Biden, did not immediately respond to a request for comment, but previously said his client “conducted himself ethically and honorably in all his business dealings.”

Keaton’s father Joey Langston was also associated with James Biden.ASSOCIATED PRESS
AFP via Getty Images

Keaton Langston agreed in September to repay Americore $240,000 in a civil settlement. James Biden agreed in 2022 to repay Americore $350,000.

The Bidens and the Langstons have been linked financially for years.

The elder Langston hosted fundraisers for Joe Biden when he was a senator, ProPublica reported.

Joey Langston also loaned James Biden $800,000, with most of the installments coming toward the end of the Obama-Biden administration in 2016, and ended up only being repaid $400,000 of the amount, he told House impeachment investigators in February.

The wealthy Mississippi lawyer pleaded guilty in 2008 and was sentenced to three years in federal prison for being part of a plot to bribe a judge in an asbestos legal fees dispute.

He was seeking to overturn his conviction when he made loans to the then-vice president’s son.

Joey Langston’s alleged co-conspirator in the bribes case, attorney Dickie Scruggs, was involved in a second prosecution for attempting to bribe a different judge.

James Biden was wiretapped by the FBI in 2007 as part of its investigation of the second bribery case, the Washington Post reported in December.

James was in talks at the time with Scruggs and conspirator Tim Balducci about setting up a law firm that would have employed himself, his nephew Hunter Biden and James’ wife Sara.

Then-Sen. Biden went from an opponent of federal legislation to sanction tobacco companies for lying about the addictiveness of cigarettes to a supporter after Scruggs — who planned a multibillion-dollar lawsuit — paid James Biden’s lobbying firm $100,000 in 1998, the Washington Post reported.

“I probably wouldn’t have hired him if he wasn’t the senator’s brother,” Scruggs told the paper.

Scruggs also flew Joe Biden to a fundraiser on his private plane, the Washington Post reported.

Joe Biden has consistently claimed he “never” discussed business with his son or brother and said in December and again in March that he “did not” interact with their partners, including foreign associates in countries where he held sway as vice president.

Evidence including photos, emails and witness statements indicate that Biden actually interacted with his son and brother’s associates from two Chinese government-linked business ventures and their patrons from KazakhstanMexicoRussia and Ukraine.

James Biden was a partner with first son Hunter in many ventures and allegedly wasn’t always coy about the angle he was pushing to investors.

“We’ve got people all around the world who want to invest in Joe Biden,” James allegedly said in the early 2000s as he and Hunter were in the process of acquiring investment bank Paradigmaccording to a 2021 book by Politico reporter Ben Schreckinger.

https://nypost.com/2024/05/27/us-news/james-biden-associate-keaton-langston-pleads-guilty-to-51m-medicare-fraud/

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

 The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the result likely isn’t what they were hoping for.

The TROP2-directed antibody-drug conjugate (ADC) has already been filed for approval by the FDA as a treatment for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior systemic therapy based on progression-free survival data from the study, with a decision due in December.

In the latest update, AZ and Daiichi Sankyo said the OS data “numerically favoured” Dato-DXd but did not reach statistical significance in the final analysis. However, they said that the totality of the results from the study supports marketing applications for the drug, which are also under review in Europe and other world markets.

AZ’s head of oncology R&D Susan Galbraith pointed out that Dato-DXd is the only investigational therapy to show a “clinically meaningful” survival improvement in these patients compared to docetaxel, currently a go-to option in patients who have failed prior targeted drugs or immunotherapies.

PFS is often used as a primary endpoint in cancer studies as it delivers an earlier readout and means drugs can be made available to patients more quickly, but it doesn’t always follow that extending the time to disease progression tracks with longer survival – and the TROPION-Lung01 data is another example of that.

Whether OS data should be a pre-requisite for new cancer drugs staying on the market in the long-term is a matter for debate, with some arguing that staving off disease progression is a key concern for patients, and it can be hard to demonstrate OS in a realistic timeframe with recent advances in the efficacy of cancer treatment. Others meanwhile say that relying on PFS means patients may think a treatment is more effective than it actually is.

The FDA and other regulators have increasingly been prepared to give accelerated approval to new cancer drugs based on PFS data, thanks in part to the rapid development of new therapies for cancer in recent years. However, there have been signs that the US agency may be shifting its thinking and placing greater emphasis on showing an OS benefit in a subsequent confirmatory trial – something that was achieved in less than half of drugs granted accelerated approval by the FDA between 2013 and 2017 in a recent analysis.

According to Daiichi Sankyo’s head of R&D Ken Takeshita, the OS trend in TROPION-Lung01 should be considered in the context of the PFS data and a more than doubling in the overall response rate and duration of response compared to docetaxel.

“These data will support our ongoing discussions with regulatory authorities globally to potentially bring datopotamab deruxtecan to patients as quickly as possible and mark another step forward in creating new standards of care for patients with cancer,” he said.

Dato-DXd is in other studies looking at its potential as a first-line therapy in NSCLC, which if positive could provide an opportunity to demonstrate a benefit for the drug on both PFS and OS as well as moving it into earlier use.

The ADC is also under a parallel review for unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease, based on the results of the TROPION-Breast01 study.

AZ licensed rights to Dato-DXd in July 2020 for $1 billion upfront, plus up to $5 billion in regulatory and sales milestones. It was the second major licensing deal between the two companies, coming after a $6.9 billion deal for HER2-directed ADC Enhertu (trastuzumab deruxtecan) in the previous year.

https://pharmaphorum.com/news/azs-dato-dxd-misses-survival-endpoint-lung-cancer-trial